Increased stability of airflow following botulinum toxin injection

Laryngoscope

Volumn 109, Issue 8, 1999, Pages 1300-1306

  Finnegan, Eileen M ^a,b   Luschei, Erich S ^a,b   Gordon, James D ^b   Barkmeier, Julie M ^c   Hoffman, Henry T ^b  

^a UNIVERSITY OF IOWA   (United States)

^b UNIVERSITY OF IOWA HOSPITALS AND CLINICS   (United States)

^c UNIVERSITY OF ARIZONA   (United States)

Author keywords

Airflow; Botulinum toxin; Spasmodic dysphonia; Vocal tremor

Indexed keywords

BOTULINUM TOXIN;

ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DYSPHONIA; FEMALE; HUMAN; INJECTION SITE; MALE; PHONATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RESPIRATORY AIRFLOW; SPEECH; TREATMENT OUTCOME;

AIR; BOTULINUM TOXINS; CROSS-OVER STUDIES; DOUBLE-BLIND METHOD; FEMALE; HUMANS; INJECTIONS, INTRAMUSCULAR; LARYNGEAL MUSCLES; MALE; MANOMETRY; MIDDLE AGED; NEUROMUSCULAR AGENTS; PULMONARY VENTILATION; VOICE DISORDERS;

EID: 0032805213     PISSN: 0023852X     EISSN: None     Source Type: Journal    
DOI: 10.1097/00005537-199908000-00021     Document Type: Article

References (22)

1. Zwirner P, Murry T, Swenson M, Woodson G. Effects of botulinum toxin therapy in patients with adductor spasmodic dysphonia: acoustic, aerodynamic, and videoendoscopic findings. Laryngoscope 1992;102:400-406.
2. Briant TDR, Blair RL, Cole P, Singer L. Laboratory investigation of abnormal voice. J Otolaryngol 1983;12:285-290.
3. Woo P, Colton R, Casper J, Brewer D. Analysis of spasmodic dysphonia by aerodynamic and laryngostroboscopic measurements. J Voice 1992;6:344-351.
4. Hirano M, Koike Y, von Leden H. Maximum phonation time and air usage during phonation. Folia Phoniatri (Basel) 1968;20:185-201.
5. Davis PJ, Boone DR, Carroll RL, Darveniza P, Harrison GA. Adductor spastic dysphonia: heterogeneity of physiologic and phonatory characteristics. Ann Otol Rhinol Laryngol 1988;97:179-185.
6. Finnegan EM, Luschei ES, Barkmeier JM, Hoffman HT. Sources of error in estimation of laryngeal airway resistance in persons with spasmodic dysphonia. J Speech Hear Disord 1996;39:105-113.
7. Woodson GE, Zwirner P, Murry T, Swenson M. Use of flexible fiberoptic laryngoscopy to assess patients with spasmodic dysphonia. J Voice 1991;5:85-91.
8. Hirano M, Ohala J. Use of hooked-wire electrodes for electromyography of the intrinsic laryngeal muscles. J Speech Hear Res 1969;12:362-373.
9. Smitheran JR, Hixon TJ. A clinical method for estimating laryngeal airway resistance during vowel production. J Speech Hear Disord 1981;46:138-146.
10. Simpson LL. The origin, structure and pharmacological activity of botulinum toxin. Pharmacol Rev 1981;33:155-188.
11. Simpson LL. Clinically relevant aspects of the mechanism of action of botulinum neurotoxin. J Voice 1992;6:358-364.
12. 125I-labeled botulinum neurotoxins with nerve terminals, I: ultrastructural autoradiographic localization and quantitation of distinct membrane acceptors for types A and B on motor nerves. J Cell Biol 1986;103:521-534.
13. 125I-labeled botulinum neurotoxins with nerve terminals, II: autoradiographic evidence for its uptake into motor nerves by acceptormediated endocytosis. J Cell Biol 1986;103:535-544.
14. Dolly JO, Black J, Williams RS, Melling J. Acceptors for botulinum neurotoxin reside on motor nerve terminal and mediate its internalization. Nature (Lond) 1984;307: 457-460.
15. Donovan JJ, Middlebrook JL. Ion-conducting channels produced by botulinum toxin in planear lipid membranes. Biochemistry 1986;25:2872-2876.
16. Burgen AS, Dickens F, Zalman LJ. The action of botulinum toxin on the neuromuscular junction. J Physiol (Lond) 1949;109:10-24.
17. Ludlow CL, Naunton RF, Fujita M, Sedory SE. Spasmodic dysphonia: botulinum toxin injection after recurrent nerve surgery. Otolaryngol Head Neck Surg 1990;102:122-131.
18. Shipp T, Izdebski K, Schutte H, Morrissey P. Subglottal air pressure in spastic dysphonia speech. Folia Phoniatr 1988; 40:105-110.
19. Ludlow CL, Hallett M, Sedory ES, Fujita M, Naunton RF. The pathophysiology of spasmodic dysphonia and its modification by botulinum toxin. In: Beradelli A, Benecke R, Manfredi M, Marsden CD, eds. Motor Disturbances, edn 2. London: Academic Press, 1990:274-288.
20. Malmgren LT. Anatomy and cell biology of the laryngeal motor neurons: implications for the treatment of spasmodic dysphonia. J Voice 1992;6:298-305.
21. Malmgren L, Olsson Y, Olsson T, Kristensson K. Uptake and retrograde axonal transport of various exogenous macromolecules in normal and crushed hypoglossal nerves. Brain Res 1978;153:477-493.
22. Adams SG, Durkin LC, Irish JC, Wong DLH, Hunt EJ. Effects of botulinum toxin type A injections on aerodynamic measures of spasmodic dysphonia. Laryngoscope 1996;106: 296-300.